A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with Covid-19 is to restart after being approved by British regulators.
A global trial designed to test whether hydroxychloroquine and chloroquine can prevent infection with Covid-19 is to restart after being approved by British regulators.
The Medicines and Healthcare Products Regulatory Agency (MHRA) took its decision on what is known as the COPCOV trial after hydroxychloroquine was found in another British trial to have no benefit as a treatment for patients already infected with Covid-19, the disease caused by the new coronavirus.
The FDA later revoked emergency use authorisation for the drugs to treat Covid-19, after trials showed they were of no benefit as treatments.
But White, who is co-leadng the COPCOV trial, said studies of the drugs as a potential preventative medicine had not yet given a conclusive answer.
